百普賽斯(301080.SZ):已成功開發近40款高質量的GMP級別產品
格隆匯11月4日丨百普賽斯(301080.SZ)於近期接受特定對象調研,就“公司GMP級試劑方面有哪些進展?”,公司表示,公司在擁有GMP級別質量管理體系平台基礎上,結合細胞治療藥物生產規範,以更加嚴格的質量管理和藥品級放行檢測標準,已成功開發近40款高質量的GMP級別產品,包括細胞因子、細胞激活用抗體和磁珠、全能核酸酶以及Cas酶等,適用於CGT藥物的規模化生產和臨牀研究。值得特別關注的是,公司位於蘇州的GMP級別生產廠房已正式投產,該工廠採用先進的工藝控制和全面的GMP級別質量管理體系,確保從源頭到成品的每一個環節都能嚴格防控外源性污染,如病毒、支原體、細菌和內毒素等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.